Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study

Table 4 Association of Lp(a) levels with recurrent CVEs in T2DM patients according to HBA1c status

Lp(a) (mg/dL)	Recurrent CVEs/Total	Crude model		Adjusted model
Lp(a) (mg/dL)	(153/2284)	HR (95% CI)	p value	HR (95% CI)	p value
Total patients	153/2284
Lp(a) per-SD increase		1.007 (1.002–1.013)	0.007	1.008 (1.002–1.014)	0.006
Lp(a) < 10	37/846	Reference		Reference
10 ≤ Lp(a) < 30	59/769	1.736 (1.151–2.619)	0.009	1.720 (1.099–2.692)	0.018
Lp(a) ≥ 30	57/669	1.960 (1.296–2.965)	0.001	2.049 (1.308–3.212)	0.002
HBA1c < 7.0%	74/1146
Lp(a) per-SD increase		1.008 (1.001–1.016)	0.024	1.009 (1.001–1.018)	0.023
Lp(a) < 10	17/427	Reference		Reference
10 ≤ Lp(a) < 30	28/373	1.968 (1.077–3.595)	0.028	1.815 (0.949–3.473)	0.072
Lp(a) ≥ 30	29/346	2.156 (1.185–3.924)	0.012	2.009 (1.051–3.840)	0.035
HBA1c ≥ 7.0%	79/1138
Lp(a) per-SD increase		1.006 (0.998–1.014)	0.122	1.009 (1.000–1.018)	0.050
Lp(a) < 10	20/418	Reference		Reference
10 ≤ Lp(a) < 30	31/402	1.520 (0.866–2.667)	0.144	1.571 (0.842–2.932)	0.155
Lp(a) ≥ 30	28/318	1.816 (1.023–3.223)	0.042	2.162 (1.148–4.073)	0.017

The adjusted model including age, sex, body mass index, currentis smoking, hypertension, dyslipidemia, family history of coronary artery disease, diseased vessels, low-density lipoprotein cholesterol, fasting blood glucose, statin and anti-diabetes drugs use
CVEs cardiovascular events, MI myocardial infarction, CVD cardiovascular disease

ISSN: 1475-2840